Data from six phase 2/3 studies showed that Stelara had a favorable safety profile through 1-year of treatment in Crohn’s disease and ulcerative colitis, according to research published in Inflammatory Bowel Diseases.

William J. Sandborn, MD, of the University of California, San Diego, and colleagues wrote that previous research — including in psoriatic disease — has demonstrated a good safety profile for the drug (ustekinumab, Janssen), but integrated analysis of combined patients with IBD, could help physicians make treatment choices.

“This increases the precision to

Full Article: